Growth databases and registries – towards understanding physiological effects of growth hormone
Authors:
A. Kodýtková; D. Zemková; S. Koloušková; J. Lebl
Authors place of work:
Pediatrická klinika 2. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Motol, Praha
Published in the journal:
Čes-slov Pediat 2020; 75 (4): 251-255.
Category:
Summary
Growth hormone (GH) has been used as a drug since 1956. Since mid-1980s, recombinant human growth hormone has been available for the treatment. The recombinant production of GH has contributed to extending the indication of treatment and significantly increasing the number of treated patients. In the past 35 years, growth databases and registers have been used to monitor the physiological effects of growth hormone treatment in routine practice by collecting clinical data about treated patients. The first and most extensive KIGS database contains data about more than 83,000 children. Based on this database, robust mathematical models have been developed, which are predicting the effects of growth hormone treatment. The GeNeSIS database contains more than 22,000 children. Simultaneously it contributed to understanding the genetic etiology of growth hormone deficiency and to assessing the potential risks of therapy. Nordinet® IOS has data on nearly 18,000 children. The last, smallest, but unique is the ECOS database, which, thanks to the web-based data collection about each injection, provide to assess the adherence and compliance of patients and their impact on the effect of therapy.
Growth databases and registers helped to understand the algorithms of growth hormone treatment, also contributed to its optimization and particularly to more effective use of financial means for the treatment.
Keywords:
treatment – database – Growth hormone – KIGS – GeNeSIS – ECOS – NordiNet® IOS
Zdroje
1. Frasier SD. The not-so-good old days: Working with pituitary growth hormone in North America 1956 to 1985. J Pediatr 1997; 131: 1–4.
2. Liu J-C, Makova KD, Adkins RM, et al. Episodic evolution of growth hormone in primates and emergence of the species specificity of human growth hormone receptor. Mol Biol Evol 2001; 18: 945–953.
3. Raben MS. Treatment of pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901–903.
4. Sumner JY. Human growth hormone: Current status of availability and usefullness. Pediatrics 1969; 44: 766–767.
5. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand 1986; 325: 1–9.
6. Dean HJ, Friesen HG. Growth hormone therapy in Canada: end of one era and beginning of another. Can Med Assoc J 1986; 135: 297–301.
7. Stochholm K, Kiess W. Long-term safety of growth hormone – a combined registry analysis. Clin Endocrinol (Oxf) 2018; 88: 515–528.
8. Ayyar VS. History of growth hormone therapy. Indian J Endocrinol Metab 2011; 15: 162–166.
9. Ranke MB, Wit JM. Growth hormone – past, present and future. Nat Rev Endocrinol 2018; 14: 285–300.
10. Lebl J, Koloušková S, Průhová Š, et al. Léčba růstovým hormonem – historie, současnost a budoucnost. Farmakoter Rev 2017; 2: 224–230.
11. Ranke MB, Lindberg A, Chatelain P, et al. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. Acta Paediatr 1999; 433: 122–125.
12. Ranke MB, Lindberg A, Chatelain P, et al. The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Horm Res 2001; 55: 44–48.
13. Ranke MB, Stubbe P, Majewsri F, et al. Spontaneous growth in Turner‘s syndrome. Acta Paediatr Scand 1988; 343: 22–30.
14. Child CJ, Zimmermann AG, Chrousos GP, et al. Safety outcomes during pediatric GH therapy: Final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab 2018; 104: 379–389.
15. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355: 610–613.
16. Pfäffle R, Land C, Schönau E, et al. Growth hormone treatment for short stature in the USA, Germany and France: 15 years of surveillance in the Genetics and Neuroendocrinology of Short-stature International Study (GeNeSIS). Horm Res Paediatr 2018; 90: 169–180.
17. Blum WF, Klammt J, Amselem S, et al. Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes. E Bio Medicine 2018; 36: 390–400.
18. Sävendahl L, Polak M, Backeljauw P, et al. Treatment of children with GH in the United States and Europe: Long-term follow-up from NordiNet® IOS and ANSWER program. J Clin Endocrinol Metab 2019; 104: 4730–4742.
19. Weber MM, Gordon MB, Höybye C, et al. Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. Growth Horm IGF Res 2020; 50: 71–82.
20. Lee PA, Germak J, Gut R, et al. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®. Int J Pediatr Endocrinol 2011; 6: 1–7.
21. Polak M, Konrad D, Pedersen BT, et al. Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet® International Outcome Study. J Clin Endocrinol Metab 2018; 31: 521–532.
22. https://www.merckgroup.com/en/news/ecos-study-2017-10-27.html.
23. Koledova E, Stoyanov G, Ovbude L, et al. Adherence and long-term growth: the easypod TM connect observational study (ECOS) in children with growth disorders. Endocr Connect 2018; 7: 1–30.
24. Cutfield WS, Derraik GB, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011; 6: 5–7.
25. De Pedro S, Murillo M, Salinas I, et al. Variability in adherence to rhGH treatment: socioeconomic causes and effect on children’s growth. Growth Horm IGF Res 2016; 26: 32–35.
26. Kodytková A, Al Lababidi E, Čermáková I, et al. Analýza dat z celostátního registru pacientů léčených růstovým hormonem REPAR. Čes-slov Pediat 2020; 75 (4): 205–212.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2020 Číslo 4
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Noonan syndrome and other RASopathies: Aetiology, diagnostic procedures and therapy
- Noonan syndrome from a paediatric cardiologistˇs perspective
- Etiology and diagnostic approach of growth failure in children born small for gestational age (SGA) with persistent short stature in childhood (SGA-SS)
- Prenatal phenotype of RASopathies